GAIN THERAPEUTICS INC

Gain Therapeutics to Present at Sidoti Small-Cap Virtual Investor Conference

12 Jan 2023 16:05:00 By Nasdaq GlobeNewswire

Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update

10 Nov 2022 16:02:00 By Nasdaq GlobeNewswire

Gain Therapeutics Presents New Preclinical Data Showing Promising Pharmacological Activity in Parkinson’s Disease Patient-Derived Dopaminergic Neurons

26 Sep 2022 08:00:02 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Promotion of Matthias Alder to Chief Executive Officer

20 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

Gain Therapeutics Presents New Preclinical Data Demonstrating Potential Disease Modifying Benefits of its Novel Brain Penetrant Small Molecule Candidate GT-02287 in Two Preclinical Models of Parkinson’s Disease

19 Sep 2022 08:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics to Present Data at Upcoming Medical Meetings

08 Sep 2022 08:00:02 By Nasdaq GlobeNewswire

Gain Therapeutics To Participate At The H.C. Wainwright 24th Annual Global Investment Conference

06 Sep 2022 08:00:03 By Nasdaq GlobeNewswire

Gain Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Business Update

08 Aug 2022 08:00:01 By Nasdaq GlobeNewswire

Gain Therapeutics to Participate at the 2022 BTIG Biotechnology Conference

04 Aug 2022 08:00:01 By Nasdaq GlobeNewswire

Gain Therapeutics to Participate at the Jefferies Healthcare Conference

02 Jun 2022 08:00:02 By Nasdaq GlobeNewswire

Gain Therapeutics to Participate at the H.C. Wainwright Global Investment Conference

18 May 2022 08:00:01 By Nasdaq GlobeNewswire

Gain Therapeutics, Inc. Reports First Quarter 2022 Financial Results and Business Update

16 May 2022 16:05:01 By Nasdaq GlobeNewswire

Gain Therapeutics Presents Positive Preclinical Data On Its Gaucher Disease Program at IWGGD Symposium

11 May 2022 09:30:00 By Nasdaq GlobeNewswire

Gain Therapeutics Presents Positive Preclinical Data on its Small Molecule Lead Compound in GBA1 Parkinson’s Disease at XXVII IAPRD World Congress

06 May 2022 08:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics to Participate in the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference

26 Apr 2022 17:18:58 By Nasdaq GlobeNewswire

Gain Therapeutics Presents Positive Data on its Small Molecule Lead Compound in GBA1 Parkinson’s Disease at the 2022 Synuclein Meeting

12 Apr 2022 13:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Presents Additional Confirmatory Data on its Gaucher Disease Program at the 2022 Glycolipid and Sphingolipid Biology Gordon Research Conference

29 Mar 2022 08:00:01 By Nasdaq GlobeNewswire

Gain Therapeutics, Inc. Reports Full Year 2021 Financial Results and Business Update

24 Mar 2022 08:00:01 By Nasdaq GlobeNewswire

Gain Therapeutics Presents Positive Data on its Structurally Targeted Allosteric Regulators in both Parkinson’s and Alzheimer’s Disease at the AD/PD 2022 Conference

15 Mar 2022 08:00:01 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Participation in Upcoming Investor and Scientific Conferences

01 Mar 2022 08:00:02 By Nasdaq GlobeNewswire